Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Babies fed with INFAT® OPO sleep more at night – thanks to newly discovered 7th health benefit - The Pharma Times | Pharma & Health Care News Portal
Categories: Health Care

Babies fed with INFAT® OPO sleep more at night – thanks to newly discovered 7th health benefit

Bengaluru, March 20, 2016: Infant formula companies who include Advanced Lipid’s INFAT® OPO in their products can now use a compelling and scientifically-proven ‘Super Comfort’ marketing proposition in association with their brands.

A series of clinical trials have demonstrated that INFAT® OPO offers four separate benefits associated with baby’s comfort. This includes new preliminary evidence that infants fed with formula containing INFAT® OPO sleep for longer over the course of 24 hours and also during the night.

In total, this means INFAT® OPO has now been demonstrated to offer seven benefits, all of which are scientifically supported.

Four of these beneficial health effects are in the area of comfort, as follows:

Night sleep (the new 7th benefit) – A double-blind randomized controlled study involving 159 healthy term infants showed that infants fed formula containing INFAT® tend to enjoy more sleep at 6 weeks and 12 weeks than babies fed with control formula

Less crying – INFAT® is clinically proven to reduce crying time by up to 75% in healthy term babies – mainly in the late afternoon and evening – during the first weeks of their lives

Gut comfort – babies fed with formula containing INFAT® enjoy similar levels of beneficial gut bacteria to those found in breast-fed babies, promoting a healthy digestion and immune system

Softer stools – INFAT® promotes softer stools and in doing so reduces incidences of hard stools by as much as 50% compared with control formula

In addition to significantly greater levels of comfort, INFAT® optimizes the uptake of calcium, fat and energy. It has also been shown that bone strength in babies fed with INFAT® is similar to that found in breast-fed babies. Finally, bringing the list of benefits to seven, INFAT® has been shown to have a protective effect against gut inflammation, thereby enhancing gut health.

INFAT® OPO as an infant formula ingredient is unique in that it is a single ingredient that has been demonstrated to offer four comfort related benefits – something no other ingredient on the market can match. This means formula manufacturers can now market their products with a ‘Super Comfort’ positioning that will appeal to parents all over the world.

Avner Avissara, CEO of Advanced Lipids, commented: “Baby’s comfort is a high priority for parents of young babies, since it impacts on the whole family. An uncomfortable infant cries more and sleeps less – leading to stress and tiredness for parents. This means formula that promises increased comfort is an appealing proposition that resonates with mothers when they shop the baby aisle in-store. With INFAT® OPO, formula manufacturers can now use the Super-Comfort positioning to stand out on-shelf and gain a significant edge on their competitors.”

With INFAT® OPO it is now possible to create a formula with a fat composition that is closer than ever to breast milk in terms of structure and benefits. Breast milk is always best for baby, but when it isn’t possible to breast-feed, formula made with INFAT® OPO offers the next best solution, so parents can be confident they are giving their child a great start in life through optimum nutrition.

INFAT® OPO is an SN2 palmitate fat ingredient that when added as the fat component to infant formula mimics the composition and properties of human milk fat.

Produced in Europe using a patented enzymatic process, INFAT® delivers structured triglycerides with a high level of palmitic acid in the mid position of the triglyceride for optimal infant development and wellbeing. It is manufactured in state-of-the-art production facilities operated by AAK, which meet all of the most stringent European quality standards.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Gleneagles Hospital Mumbai Introduces Pediatric Bone Marrow Transplant (BMT) Facility

New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…

20 hours ago

Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT);

Achieves significant advancement in Cancer Treatment to Enhance Quality of Life  As per the National…

2 days ago

Two Complex Robotic Kidney Transplant Surgeries Successfully Performed at Fortis Hospital Bannerghatta Road

-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…

3 days ago

On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology Nurses

Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…

4 days ago

SOCC Unveils A New Era In Paediatric Care: Second Opinion Online Consultations For Children

Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…

7 days ago

India’s First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka’s 1st Robotic Nipple Sparing Mastectomy

Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…

1 week ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420